Histogen CEO Presents Extracellular Matrix Data for the First Time at MD&M West
Embryonic extracellular matrix contains unique composition of proteins for rapid cell proliferation and healing without scars
SAN DIEGO, January 31, 2008 - Gail
Naughton, CEO of Histogen, Inc., a regenerative medicine company
developing solutions based on the products of newborn fibroblasts, will
present data on the company's unique embryonic extracellular matrix
(ECM) today at the MD&M West Conference in Anaheim, Calif.
Through the company's proprietary bioreactor
technology, Histogen is uniquely capable of simulating the embryonic
environment, including hypoxic conditions of 1-5% oxygen, creating a
human extracellular matrix with a wide distribution of embryonic
proteins unmatched by adult ECM.
"Histogen's human extracellular matrix contains a
variety of proteins found only in the embryonic environment," said Dr.
Robert Kellar, VP of Research and Development at Histogen. "Our human
ECM provides the benefits of a natural biologic for surface modification
and tissue regeneration, without the problems of allergic responses and
possible viral transmission associated with porcine and bovine derived
materials."
Under these hypoxic culture conditions, over
5,000 genes are differentially expressed as compared to cells grown
under traditional tissue culture conditions. These distinct genes may be
responsible for encouraging increased wound healing and regeneration.
"It is well known that operations performed in
the prenatal environment will not leave scars present at birth," said
Dr. Gail Naughton, CEO of Histogen. "To be able to replicate this rapid,
scarless healing in adult patients would mean countless benefits in the
areas of plastic and general surgery. The regenerative capabilities of
the embryonic-like matrix also support its use as a coating for medical
devices and as patches for hernia and soft tissue repair."
Histogen, launched in 2007, seeks to redefine
regenerative medicine by developing a series of high value products
without the use of embryonic stem cells or animal products. Through
Histogen's proprietary bioreactors that mimic the embryonic environment,
newborn fibroblasts are encouraged to naturally produce the vital
proteins and growth factors from which the company has developed its
rich product portfolio. Histogen's business plan benefits from the
lessons learned at Advanced Tissue Sciences, and focuses on near, mid
and long term products that are either self-pay or reimbursable.
0 comment :
Thanks for your comments.